Alzheimer's disease: New therapeutic strategies

Research output: Contribution to journalReview articleResearchpeer-review

7 Citations (Scopus)


© 2014 Elsevier Espana, S.L.U. Todos los derechos reservados. The rapid increase in prevalence rates of Alzheimer's disease means that treatments to prevent, stop or reverse this devastating disease are urgently needed. Despite advances in understanding its molecular pathology, there are no drugs that can halt its progression. This review takes a tour through phase 2, or higher studies, probing receptor agonist agents interfering with aggregation, inhibitors/modulators of secretases, lipid-lowering agents, and, finally and most extensively, immunotherapy. The fact that phase 3 studies with bapineuzumab and solaneuzumab have recently failed does not invalidate the potential of immunotherapy, as more information is available and new clinical trials are being initiated.
Original languageEnglish
Pages (from-to)76-83
JournalMedicina Clinica
Issue number2
Publication statusPublished - 20 Jul 2015


  • Alzheimers disease
  • Amyloid-β
  • Immunotherapy
  • New therapies
  • Vaccine


Dive into the research topics of 'Alzheimer's disease: New therapeutic strategies'. Together they form a unique fingerprint.

Cite this